CLEVELAND, April 5 (UPI) -- U.S. firm Cleveland BioLabs said Thursday it is ready to launch a phase 2 study of its prostate cancer drug Curaxin CBLC102.
The study wil enroll 31 patients with advanced, hormone-refractory (androgen independent) prostate cancer.
The two-year study -- to be conducted at the University of Chicago, the Cleveland Clinic and the University Hospitals of Cleveland -- will assess the patients' reduction in PSA levels, reduction in tumor size, and disease-free survival.
"CBLC102's historic safety profile has proven consistent and the hormone-refractory prostate cancer trial is advancing in line with our expectations," said Cleveland BioLabs President and CEO Michael Fonstein. "CBLC102 is the most advanced compound in our anti-cancer (Curaxin) pipeline ..."
